Literature DB >> 10440378

Essential role for oncogenic Ras in tumour maintenance.

L Chin1, A Tam, J Pomerantz, M Wong, J Holash, N Bardeesy, Q Shen, R O'Hagan, J Pantginis, H Zhou, J W Horner, C Cordon-Cardo, G D Yancopoulos, R A DePinho.   

Abstract

Advanced malignancy in tumours represents the phenotypic endpoint of successive genetic lesions that affect the function and regulation of oncogenes and tumour-suppressor genes. The established tumour is maintained through complex and poorly understood host-tumour interactions that guide processes such as angiogenesis and immune sequestration. The many different genetic alterations that accompany tumour genesis raise questions as to whether experimental cancer-promoting mutations remain relevant during tumour maintenance. Here we show that melanoma genesis and maintenance are strictly dependent upon expression of H-RasV12G in a doxycycline-inducible H-Ras12G mouse melanoma model null for the tumour suppressor INK4a. Withdrawal of doxycycline and H-RasV12G down-regulation resulted in clinical and histological regression of primary and explanted tumours. The initial stages of regression involved marked apoptosis in the tumour cells and host-derived endothelial cells. Although the regulation of vascular endothelial growth factor (VEGF) was found to be Ras-dependent in vitro, the failure of persistent endogenous and enforced VEGF expression to sustain tumour viability indicates that the tumour-maintaining actions of activated Ras extend beyond the regulation of VEGF expression in vivo. Our results provide genetic evidence that H-RasV12G is important in both the genesis and maintenance of solid tumours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440378     DOI: 10.1038/22788

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  269 in total

1.  Glioblastoma multiforme: the terminator.

Authors:  E C Holland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.

Authors:  M Kortylewski; P C Heinrich; M E Kauffmann; M Böhm; A MacKiewicz; I Behrmann
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 3.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 4.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

5.  Depot formation of doxycycline impairs Tet-regulated gene expression in vivo.

Authors:  Kathleen Anders; Christian Buschow; Jehad Charo; Thomas Blankenstein
Journal:  Transgenic Res       Date:  2011-12-14       Impact factor: 2.788

6.  Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis.

Authors:  H Roelofs; M C Mostert; K Pompe; G Zafarana; M van Oorschot; R J van Gurp; A J Gillis; H Stoop; B Beverloo; J W Oosterhuis; C Bokemeyer; L H Looijenga
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

7.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 8.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

9.  Inducible expression of FGF-3 in mouse mammary gland.

Authors:  Elly S W Ngan; Zhi-Qing Ma; Steven S Chua; Francesco J DeMayo; Sophia Y Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

10.  Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.

Authors:  Amer M Mirza; Stephan Gysin; Nisar Malek; Kei-ichi Nakayama; James M Roberts; Martin McMahon
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.